<DOC>
	<DOCNO>NCT01170104</DOCNO>
	<brief_summary>To evaluate time progression combination therapy Transcatheter Arterial Chemoembolization ( TACE ) sorafenib patient previously untreated advanced metastatic hepatocellular carcinoma .</brief_summary>
	<brief_title>Trial Transcatheter Arterial Chemoembolization ( TACE ) With Sorafenib Locally Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Unresectable Hepatocellular carcinoma local liver lesion treatable TACE 2 . Age &gt; 18 year . 3 . ECOG Performance Status 0 1 . 4 . ChildPugh class A ( class B could include Childs score 7 ) . 5 . Life expectancy least 12 week . 6 . Subjects least one measurable lesion . 7 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count &gt; 75,000/Î¼l Total bilirubin &lt; 1.5 time upper limit normal ALT AST &lt; 2.5 x upper limit normal ( UNL ) Alkaline phosphatase &lt; 5 x ULN PTINR/PTT &lt; 1.5 x upper limit normal Serum creatinine &lt; 1.5 x ULN 8 . Signed date informed consent start specific protocol procedure 1 . History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 mo prior study entry allow ) ; cardiac arrythmias require antiarrythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . 2 . History HIV infection . 3 . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) 4 . Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) 5 . Patients seizure disorder require medication ( steroids antiepileptic ) 6 . History organ allograft The organ allograft may allow protocol specific . 7 . Patients evidence history uncontrolled bleeding diathesis 8 . Patients undergoing renal dialysis 9 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry . 10 . Excluded therapy medication , previous concomitant : Anticancer chemotherapy immunotherapy study within 4 week study entry Radiotherapy study within 3 week start study drug . ( Palliative radiotherapy allow ) . Major surgery within 4 week start study Investigational drug therapy outside trial within 4 week study entry Prior exposure study drug . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial ( men least 3 month last administration study medication ) . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Any condition unstable could jeopardize safety patient compliance study Patients unable swallow oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>TACE</keyword>
	<keyword>locally , advance Hepatocellular Carcinoma</keyword>
</DOC>